Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products, primarily in the healthcare sector.
Business. Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd (2566.HK) is a pharmaceutical company headquartered in Hangzhou. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research. It is primarily listed on the Hong Kong Stock Exchange. The company generates revenue through the sale of its pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd (2566.HK) is a pharmaceutical company headquartered in Hangzhou. The firm operates within the healthcare sector, specifically focusing on pharmaceuticals and medical research. It is primarily listed on the Hong Kong Stock Exchange. The company generates revenue through the sale of its pharmaceutical products.
The company's capital structure is characterized by a market capitalization of 1.49 billion CNY, with a market price of 6.16 CNY per share. The shares outstanding are 241.52 million for both basic and diluted shares, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Without access to key profitability indicators such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess the company's performance relative to industry medians or to evaluate its return on invested capital.
The company's segment and geographic exposure are not disclosed in the available data. There is no information on revenue concentration by product line or geographic region, which limits the ability to assess exposure to specific markets or product categories.
Growth trajectory is not quantified in the available data. No outlook figures or revenue history are provided to assess the company's current or future growth potential. The absence of forward-looking guidance or historical performance data makes it difficult to evaluate the company's trajectory.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. The dilution risk is currently low, as there is no evidence of dilution from recent issuance or capital-raising activities. No adjustments have been applied to the valuation metrics, and no specific dilution sources are identified in the available data.
Recent events, including filings or transcripts, are not disclosed in the available data. There is no information on recent regulatory filings, earnings calls, or other public disclosures that could provide insight into the company's operations or strategic direction.
- The company has a market capitalization of 1.49 billion CNY, with no immediate dilution pressure from share issuance.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- Profitability and return metrics are not available, limiting the ability to compare the company's performance to industry benchmarks.
- Growth trajectory and revenue history are not disclosed, making it difficult to evaluate the company's future potential.
- Segment and geographic exposure are not provided, limiting visibility into the company's market diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd Market data — financials · 2026-05-26